Arima Hiroshi, Cheetham Timothy, Christ-Crain Mirjam, Cooper Deborah, Gurnell Mark, Drummond Juliana B, Levy Miles, McCormack Ann I, Verbalis Joseph, Newell-Price John, Wass John A H
Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Japan Endocrine Society.
Endocr Connect. 2022 Oct 14;11(11). doi: 10.1530/EC-22-0378. Print 2022 Nov 1.
'What's in a name? That which we call a rose/By any other name would smell as sweet' (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare's implication is that a name is nothing but a word, and it therefore represents a convention with no intrinsic meaning. While this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rationale for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology, and pediatric endocrine societies now proposes changing the name of 'diabetes insipidus' to 'arginine vasopressin deficiency (AVP-D)' for central etiologies, and 'arginine vasopressin resistance (AVP-R)' for nephrogenic etiologies. This article provides both the historical context and the rationale for this proposed name change.
“名字中有什么呢?我们所称的玫瑰,换个名字闻起来也一样芬芳”(朱丽叶语,出自威廉·莎士比亚的《罗密欧与朱丽叶》)。莎士比亚的言下之意是,名字不过是个词,因此它代表的是一种没有内在意义的约定俗成。虽然这可能适用于浪漫文学,但疾病名称在医学中确实有着实际意义和影响。因此,对于一个有着数百年历史背景的疾病名称进行更改,必须有非常充分的理由。一个由来自国家和国际内分泌学以及儿科内分泌学会的代表组成的工作组,现提议将“尿崩症”更名为:对于中枢性病因,称为“精氨酸加压素缺乏症(AVP - D)”;对于肾性病因,称为“精氨酸加压素抵抗症(AVP - R)”。本文既提供了这一拟议更名的历史背景,也阐述了其理由。